Rachel Riechelmann: Low dose Everolimus for patients with Neuroendocrine tumors
Rachel Riechelmann, Director of the Clinical Oncology Department and Professor at AC Camargo Cancer Center, shared an article on X:
“Low dose (LD: ~ 5mg/d) Everolimus similar time to treatment failure to high dose (HD) for pts with Neuroendocrine tumors.
Our retrospective multi center data.
Less dose, less tox, less cost.
We need more dose optimization studies in oncology!”
The Efficacy of a Lower Dose of Everolimus in Patients with Advanced Neuroendocrine Tumors.
Authors: Rodrigo G. Taboada, et al.
Dr. Rachel Riechelmann is the Director of the Clinical Oncology Department and Professor at AC Camargo Cancer Center, Sao Paulo, Brazil and also serves as the President of the Brazilian GI Tumors Group (GTG). Prof. Riechelmann is a member of ESMO Scientific Committees (Colorectal and NET), Latin American Society of GI Oncology (SLAGO), the European Society of Neuroendocrine Tumors Advisory Board and Chair – GI LACOG (Latin American Cooperative Oncology Group).
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023